

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/019826 A1

(51) International Patent Classification⁷: **G01N 33/574**,
33/68

(21) International Application Number:
PCT/GB2004/003564

(22) International Filing Date: 18 August 2004 (18.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0319376.0 18 August 2003 (18.08.2003) GB

(71) Applicant (for all designated States except US):
CHROMA THERAPEUTICS LIMITED [GB/GB];
92 Milton Park, Abingdon, Oxon OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAWDEN, Lindsay**,
Jane [GB/GB]; Chroma Therapeutics Limited, 92 Milton
Park, Abingdon, Oxon OX14 4RY (GB). **BONE, Eliza-**
beth, Ann [GB/GB]; Chroma Therapeutics Limited, 92
Milton Park, Abingdon, Oxon OX14 4RY (GB). **DRUM-**
MOND, Alan, Hastings [GB/GB]; Chroma Therapeutics

Limited, 92 Milton Park, Abingdon, Oxon OX14 4RY
(GB). **NEEDHAM, Lindsey, Ann** [GB/GB]; Chroma
Therapeutics Limited, 92 Milton Park, Abingdon, Oxon
OX14 4RY (GB).


(74) Agents: **SUTCLIFFE, Nicholas** et al.; Mewburn Ellis
LLP, York House, 23 Kingsway, London, Greater London
WC2B 6HP (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: DETECTION OF HISTONE MODIFICATION IN CELL-FREE NUCLEOSOMES



(57) Abstract: This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the analysis of cell-free nucleosomes in samples from individuals. Methods of the invention may include contacting cell-free nucleosomes from a biological fluid sample obtained from the individual with an antibody that binds specifically with a modified histone protein. Binding of the antibody to the nucleosomes is indicative that the individual has the disease condition.



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.